Literature DB >> 24067184

Continuous positive airway pressure treatment for acute mountain sickness at 4240 m in the Nepal Himalaya.

Pamela L Johnson1, Claire C Johnson, Prasanta Poudyal, Nirajan Regmi, Megan A Walmsley, Buddha Basnyat.   

Abstract

Acute mountain sickness (AMS) is very common at altitudes above 2500 m. There are few treatment options in the field where electricity availability is limited, and medical assistance or oxygen is unavailable or difficult to access. Positive airway pressure has been used to treat AMS at 3800 m. We hypothesized that continuous positive airway pressure (CPAP) could be used under field conditions powered by small rechargeable batteries. Methods Part 1. 5 subjects trekked to 3500 m from 2800 m in one day and slept there for one night, ascending in the late afternoon to 3840 m, where they slept using CPAP 6-7 cm via mask. The next morning they descended to 3500 m, spent the day there, ascended in late afternoon to 3840 m, and slept the night without CPAP. Continuous overnight oximetry was recorded and the Lake Louise questionnaire for AMS administered both mornings. Methods Part 2. 14 trekkers with symptoms of AMS were recruited at 4240 m. All took acetazolamide. The Lake Louise questionnaire was administered, oximetry recorded, and CPAP 6-7 cm was applied for 10-15 min. CPAP was used overnight and oximetry recorded continuously. In the morning the Lake Louise questionnaire was administered, and oximetry recorded for 10-15 min. The equipment used in both parts was heated, humidified Respironics RemStar® machines powered by Novuscell™ rechargeable lithium ion batteries. Oximetry was recorded using Embletta™ PDS. Results Part 1. CPAP improved overnight Sao2 and eliminated AMS symptoms in the one subject who developed AMS. CPAP was used for 7-9 h and the machines operated for >8 h using the battery. Results Part 2. CPAP use improved Sao2 when used for 10-15 min at the time of recruitment and overnight CPAP use resulted in significantly reduced AMS symptoms. Conclusion. CPAP with rechargeable battery may be a useful treatment option for trekkers and climbers who develop AMS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067184      PMCID: PMC5206702          DOI: 10.1089/ham.2013.1015

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  17 in total

1.  Everest or bust: a cross sectional, epidemiological study of acute mountain sickness at 4243 meters in the Himalayas.

Authors:  B Basnyat; J Lemaster; J A Litch
Journal:  Aviat Space Environ Med       Date:  1999-09

Review 2.  Acute mountain sickness: controversies and advances.

Authors:  Peter Bartsch; Damian M Bailey; Marc M Berger; Michael Knauth; Ralf W Baumgartner
Journal:  High Alt Med Biol       Date:  2004       Impact factor: 1.981

3.  Acute mountain sickness is related to nocturnal hypoxemia but not to hypoventilation.

Authors:  P Erba; S Anastasi; O Senn; M Maggiorirni; K E Bloch
Journal:  Eur Respir J       Date:  2004-08       Impact factor: 16.671

4.  Prevention of acute mountain sickness by low positive end-expiratory pressure in field conditions.

Authors:  Jean-Claude Launay; Olivier Nespoulos; Angélique Guinet-Lebreton; Yves Besnard; Gustave Savourey
Journal:  Scand J Work Environ Health       Date:  2004-08       Impact factor: 5.024

5.  Acute mountain sickness is associated with sleep desaturation at high altitude.

Authors:  Keith R Burgess; Pamela Johnson; Natalie Edwards; Jackie Cooper
Journal:  Respirology       Date:  2004-11       Impact factor: 6.424

6.  Positive end expiratory pressure as a method for preventing acute mountain sickness.

Authors:  G Savourey; R Caterini; J C Launay; A Guinet; Y Besnard; A M Hanniquet; J Bittel
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1998

7.  Continuous positive airway pressure increases haemoglobin O2 saturation after acute but not prolonged altitude exposure.

Authors:  Piergiuseppe Agostoni; Gianluca Caldara; Maurizio Bussotti; Miriam Revera; Mariaconsuelo Valentini; Francesca Gregorini; Andrea Faini; Carolina Lombardi; Gregorz Bilo; Andrea Giuliano; Fabrizio Veglia; Giulio Savia; Pietro A Modesti; Giuseppe Mancia; Gianfranco Parati
Journal:  Eur Heart J       Date:  2009-11-10       Impact factor: 29.983

8.  Non-invasive positive pressure ventilation during sleep at 3800 m: Relationship to acute mountain sickness and sleeping oxyhaemoglobin saturation.

Authors:  Pamela L Johnson; Daniel A Popa; G Kim Prisk; Natalie Edwards; Colin E Sullivan
Journal:  Respirology       Date:  2009-12-27       Impact factor: 6.424

9.  Auto-PEEP in the therapy of AMS in one person at 4,330 m.

Authors:  Markus Tannheimer; Sibylle Tannheimer; Alfred Thomas; Michael Engelhardt; Roland Schmidt
Journal:  Sleep Breath       Date:  2008-12-04       Impact factor: 2.816

10.  Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.

Authors:  Buddha Basnyat; Jeffrey H Gertsch; Peter S Holck; E William Johnson; Andrew M Luks; Benjamin P Donham; Ross J Fleischman; Daniel W Gowder; Jason S Hawksworth; Brett T Jensen; Richard J Kleiman; Adam H Loveridge; Elizabeth B Lundeen; Sheri L Newman; Jesse A Noboa; Daniel P Miegs; Kenneth A O'Beirne; Kelly B Philpot; Miriam N Schultz; Matthew C Valente; Mandie R Wiebers; Erik R Swenson
Journal:  High Alt Med Biol       Date:  2006       Impact factor: 1.981

View more
  1 in total

1.  High Altitude Pulmonary Edema in a Healthy Pediatric Patient Traveling from Denver to Breckenridge.

Authors:  Matthew Adamo; Kayla E Prokopakis; Todd Bolotin
Journal:  Open Access Emerg Med       Date:  2022-01-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.